Firebrick Pharma secures key Nasodine patent in Canada

Firebrick Pharma (ASX:FRE) has achieved a regulatory milestone in North America with the Canadian Intellectual Property Office accepting a critical new patent for its flagship product, Nasodine Nasal Spray.

This marks the second Nasodine-related patent granted in Canada, following an earlier approval focused on the common cold.

The newly accepted patent, titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes", specifically protects the use of povidone-iodine preparations to reduce the viral load and shedding of SARS-CoV-2 within the nasal passages.

Beyond immediate treatment, the granted claims notably extend to pre-exposure prophylaxis, offering a preventative layer for individuals before they are exposed to the virus.

The intellectual property protection is set to remain in effect until 2040, securing Firebrick Pharma's commercial runway in the region for nearly two decades.

The Canadian acceptance mirrors a broader international trend for the company; similar patents have already been granted or accepted in the United States, Europe, and Australia.

At the time of reporting, Firebrick Pharma’s share price was $0.045.